Trial Into Antioxidant for Parkinson’s Disease Yields Disappointing Results

Allan I. Fleming

By Cara MurezHealthDay Reporter

FRIDAY, Sept. seventeen, 2021 (HealthDay News) – Scientists hoped to display that the normal antioxidant urate could hold off Parkinson’s disease development, but a review concluded at Massachusetts Common Healthcare facility dashed individuals anticipations.

The demo enrolled almost 300 folks recently identified with early Parkinson’s disease, which affects the body’s motor method. Signs and symptoms these kinds of as tremors, stiff limbs and harmony difficulties progress little by little, and there is no acknowledged remedy.

The exploration staff located no sizeable variation in the amount of disease development for individuals presented the metabolite inosine for two a long time when compared to the placebo group.

Inosine raises amounts of urate in the mind and blood. It has appeared neuroprotective in preclinical models.

The inosine did not prove helpful, and individuals who obtained it also had an elevated amount of kidney stones, in accordance to the review.

“The convergence of epidemiological, biological and clinical knowledge from previous exploration made a persuasive argument that elevating urate, the main antioxidant circulating in the blood, could secure in opposition to the oxidative damage assumed to play a role in Parkinson’s disease,” mentioned senior writer Dr. Michael Schwarzschild, a neurologist at Mass Common and a professor of neurology at Harvard Clinical College.

“When our review did not rule out a protecting effect of urate in Parkinson’s, it evidently confirmed that increasing urate did not slow disease development based mostly on clinical assessments and serial bran scan,” he extra in a hospital information release.

However it did not offer solutions to disease development, Schwarzschild mentioned the review was profitable in other techniques.

“The conclusions were being extremely helpful in giving a reality test that now makes it possible for the subject to go on to other therapeutic strategies,” mentioned Schwarzschild. “We also realized a lot in phrases of clinical trials science for Parkinson’s, and techniques to carry out upcoming experiments that will raise their likelihood of achievements.”

The conclusions were being published Sept. fourteen in the Journal of the American Clinical Association.

Extra details

The Parkinson’s Basis has additional on Parkinson’s disease.

Supply: Massachusetts Common Healthcare facility-Harvard College, information release, Sept. fourteen, 2021

Next Post

New Drug Combo Boosts Survival Against Aggressive Form of Breast Cancer

By Denise Mann HealthDay Reporter MONDAY, Sept. twenty, 2021 (HealthDay News) — New exploration provides good news for girls with an intense HER2-beneficial breast cancer. A specific therapy, trastuzumab deruxtecan (T-DXd), offered as Enhertu, triples the length of time that the cancer continues to be in verify when as opposed […]